Biotech News

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

Humacyte (HUMA)Humacyte2026-10-15 12:00 ESTCommercial

– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build, driven by expanding hospital orders and surgeon interest. DURHAM, N.C., Oct.

Related news

HUMAHumacyte2026-04-24 12:00 EST

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

HUMAHumacyte2026-08-18 12:00 EST

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

View all latest news

Humacyte

Bioengineered Human Tissue Platform Humacyte develops implantable vascular conduits manufactured from human vascular cells and designed to become repopulated by the patient's own cells. The platform is intended to produce universally implantable tissues at commercial scale. SYMVESS SYMVESS is an FDA-approved acellular tissue-engineered...

Recent company news

HUMAHumacyte2026-10-15 12:00 EST

Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals

HUMAHumacyte2026-10-12 12:00 EST

Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026

HUMAHumacyte2026-09-28 12:00 EST

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

HUMAHumacyte2026-09-10 12:00 EST

Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference

HUMAHumacyte2026-09-09 12:00 EST

Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months

Stock data

Close: 0.41 USD
Market cap: 308.61M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States